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a b s t r a c t
SAHA, an inhibitor of histone deacetylase activity, has been shown to sensitize tumor cells to apoptosis
induced by TRAIL, a member of TNF-family. In this paper we investigated the effect of SAHA/TRAIL
combination in two breast cancer cell lines, the ERapositive MCF-7 and the ERanegative MDA-MB231.
Treatment of MDA-MB231 and MCF-7 cells with SAHA in combination with TRAIL caused detachment of
cells followed by anoikis, a form of apoptosis which occurs after cell detachment, while treatment with
SAHA or TRAIL alone did not produce these effects. The effects were more evident in MDA-MB231 cells,
which were chosen for ascertaining the mechanism of SAHA/TRAIL action. Our results show that SAHA
decreased the level of c-FLIP, thus favouring the interaction of TRAIL with the speciﬁc death receptors
DR4 and DR5 and the consequent activation of caspase-8. These effects increased when the cells were
treated with SAHA/TRAIL combination. Because z-IEDT-fmk, an inhibitor of caspase-8, prevented both
the cleavage of the focal adhesion-kinase FAK and cell detachment, we suggest that activation of caspase-
8 can be responsible for both the decrement of FAK and the consequent cell detachment. In addition,
treatment with SAHA/TRAIL combination caused dissipation of DJm, activation of caspase-3 and
decrement of both phospho-EGFR and phospho-ERK1/2, a kinase which is involved in the phosphory-
lation of BimEL. Therefore, co-treatment also induced decrement of phospho-BimEL and a concomitant
increase in the dephosphorylated form of BimEL, which plays an important role in the induction of
anoikis.
Our ﬁndings suggest the potential application of SAHA in combination with TRAIL in clinical trials for
breast cancer.
 2011 Elsevier Masson SAS. All rights reserved.
1. Introduction
Breast cancer is the most common form of cancer diagnosed in
women. Despite the beneﬁcial effects of estrogens in women’s
health, there is a plethora of evidence that suggests an important
role of these hormones, particularly 17beta-estradiol (E2), in the
development and progression of breast cancer [1,2].
Estrogens are known to mediate their diverse functions through
two speciﬁc intracellular receptors, estogen receptor (ER)-alpha
and -beta [3]. Estrogen receptors occur in about two-thirds of
breast tumors, and the presence of ER seems to be an important
prognostic factor in breast cancer [4]. The more favourable prog-
nosis of ER-positive tumors appears to be due to their better
response to anti-hormone therapy as compared with ER-negative
tumors [5]. Endocrine therapy for hormone-dependent breast
cancers is based on the employment of estrogen antagonists, such
as tamoxifen [6], which inhibits the binding of estrogens to their
receptors, or aromatase inhibitors, which prevent estrogens
synthesis [7]. Tumors that are negative for estrogen receptors are
poorly differentiated, associated with a higher recurrence rate and
unresponsive to endocrine therapy [8].
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL),
a member of the tumor necrosis factor (TNF)-family, is a promising
candidate for cancer therapeutics due to its ability to induce
apoptosis selectively in cancer cells [9]. TRAIL activates apoptosis
upon binding to speciﬁc cell-surface death receptors (TRAIL-R1/DR4
and TRAIL-R2/DR5) in a wide variety of human tumor cell lines [10].
Moreover, TRAIL and some agonist antibodies are currently studied
in patients in clinical phases I and II trials [11,12].
Several tumor cells, including breast cancer cells, are resistant to
TRAIL [13,14]. However, resistance to TRAIL-mediated apoptosis can
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be overcome by combining TRAIL with many compounds, such as
anticancer cytotoxic drugs, proteasome inhibitors, or hystone
deacetylase (HDAC) inhibitors [15e17].
HDAC inhibitors are a new class of anticancer drugs, which
have shown signiﬁcant antiproliferative activity against a spec-
trum of hematological and solid tumors [18,19]. Our previous
studies demonstrated the ability of suberoylanilide hydroxamic
acid (SAHA), an inhibitor of HDAC, to sensitize human hep-
atocarcinoma cells to TRAIL-induced apoptosis by enhancing the
expression of DR5 and decreasing the level of the anti-apoptotic
factor c-FLIP [20].
It has been reported that MDA-MB231 cells, which are ERa-
negative breast cancer cells, exhibit a reduced sensitivity to TRAIL-
induced apoptosis [21]. Hovewer HDAC inhibitors are capable of
sensitizing MDA-MB231 cells to TRAIL [22,23]. The present study
shows that SAHA/TRAIL co-treatment induced detachment of
MDA-MB231 cells, followed by anoikis, a speciﬁc form of apoptosis
observed in cells deprived of the adhesion-derived signals. Co-
treatment induced detachment and anoikis also in MCF-7 cells,
which are ERa-positive cells, although the effects were less evident
than in MDA-MB231 cells. Our results show that these effects
were correlated with a number of events, such as the decrements
in the levels of c-FLIP, FAK, EGFR and phospho-BimEL, and the
concomitant increment in dephospho-BimEL, the form which
exerts a fundamental role in the induction of anoikis [24].
2. Materials and methods
2.1. Chemicals and reagents
TRAIL signalling has been activated using a soluble human
recombinant TRAIL/APO2L, containing the residues of aminoacids
from 114 to 281 of natural TRAIL. This compound was purchased
from Pepro Tech. (EC Ltd, London, UK) and is reported in this paper
as “TRAIL”. AG1478, a selective inhibitor of the EGFR tyrosine
kinase, was supplied from Calbiochem UK. z-IEDT-fmk from Clon-
tech (Palo Alto, CA). All the other compounds were from Sigma
(St. Louis, MO). SAHA was kindly provided by Italfarmaco S.p.a.
(Milan, Italy). Stock solutions of SAHAwere dissolved in DMSO and
diluted in culture medium. In each experimental condition, DMSO
never exceeded 0.04% and this percentagewas not toxic and did not
interfere with cell growth.
2.2. Cell cultures, cell viability and cell death assay
MDA-MB231 cells andMCF-7, obtained from “Istituto Scientiﬁco
Tumori” (Genoa, Italy), were grown as monolayers in DMEM
medium supplemented with 10% (v/v) heat inactivated foetal calf
serum (FCS) and 1 mM sodium pyruvate, at 37 C in a humidiﬁed
atmosphere containing 5% CO2. After plating on 6-well plates, cells
were allowed to adhere overnight and then treated with chemicals
or vehicle only. When the cells were treated with SAHA/TRAIL
combination, analyses were performed after separation of detached
from adherent cells. The number of viable cells was determined by
trypan blue exclusion and counting on a haemocytometer.
Distribution of cells throughout the cell cycle phases was
ascertained by ﬂow cytometric analysis using a Beckman Coulter
Epics XL cytometer as previously reported [19]. In addition,
apoptotic cells were detected by ﬂow cytometry using the annexin
V-FITC Apoptosis Detection Kit I (BD Biosciences Pharmingen; San
Diego, CA), according to the manufacturer’s instructions.
The presence of condensed chromatin was assessed using
Hoechst 33342 staining. In brief, cells were exposed to 2.5 mg/mL of
Hoechst 33342 at 37 C for 30 min. Then, Hoechst solution was
removed and the cells were rinsed with PBS and incubated in fresh
medium in the presence of the drugs. Nuclear morphology was
observed under a ﬂuorescence microscope. Apoptotic cells appear
as a strong bright blue color due to the chromatin condensation
characteristic of apoptotic cells, while normal healthy cells appear
a uniform blue.
Mitochondrial transmembrane potential (DJm) was measured
by using 3,3-dihexyloxacarbocyanine (DiOC6 Molecular Probes,
Eugene, OR), a ﬂuorochrome which exclusively emits within the
spectrum of green light and accumulates in the mitochondrial
matrix under the inﬂuence of DJm. Cells were incubated with
40 nM DiOC6 for 20 min at 37 C, washed twice with PBS and
analysed by ﬂow cytometry on Beckman Coulter Epics XL ﬂow
cytometer with excitation and emission settings of 488 and 525 nm
respectively. The percentage of cells showing a lower ﬂuorescence,
reﬂecting loss of mitochondrial transmembrane potential, was
determined by comparison with untreated control using Expo32
software. Carbonyl cyanide m-chlorophenylhydrazone (CCCP,
50 mM), a protonophore that completely de-energizes mitochon-
dria by dissipating the transmembrane potential, was used as
a positive control for maximum DJm disruption.
2.3. Cell detachment assays
Tissue culture plates were coated with poly-HEMA [poly(2-
hydroxyethylmethacrylate); SigmaeAldrich, Castle Hill, NSW,
Australia] as follows: 1 ml of 10 mg/ml of poly-HEMA in 95%
ethanol was applied to each well and allowed to dry. After drying,
the wells were washed in PBS and stored dry until used. Cells were
plated onto poly-HEMA-coated wells at 1  105 cells per well in
a six-well plate. At the indicated times, cells were harvested from
poly-HEMA-coated wells by centrifugation.
2.4. Western blotting analysis
Cell lysates were prepared as reported [25]. Protein samples
(30 mg/lane) were subjected to SDS polyacrylamide gel electro-
phoresis and then transferred to a nitrocellulose membrane for
detection with speciﬁc antibodies. Pro-caspase-8, pro-caspase-3
and Bim antibodies were obtained from Cell Signalling Technology
(Beverly, MA); DR4 and DR5 antibodies from ProSci Incorporated
(San Diego, CA); all the other antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA). Protein bands were developed by
Enhanced ChemiLuminescence (Pierce, Rockford, IL) and their
intensity was quantiﬁed by using Quantity One quantiﬁcation
analysis software (Bio-Rad, Hercules, CA). The correct protein
loading was ascertained bymeans of both red Ponceau staining and
immunoblotting for actin.
2.5. Statistical analysis
Data are presented as means  S.D. from at least three inde-
pendent experiments. Statistical analysis of the datawas performed
by Student’s t-test. P-values <0.05 were considered statistically
signiﬁcant.
2.6. Down-regulation of endogenous c-FLIP and EGFR expression
Speciﬁc siRNAs against c-FLIP and EGFR, delivered by St Cruz
Biotechnology (Santa Cruz, CA) as pools of double-stranded RNA
oligonucleotides, were transfected into the cells (2  105 cells) at
a ﬁnal concentration of 80 nM siRNA in the presence of 6 ml Met-
afectene Pro (Biontex, Martinsried/Planegg, GmBH) in a ﬁnal
volume of 1 ml serum-free DMEM. The reaction was stopped after
5 h of treatment, replacing the mediumwith DMEM þ 20% FBS and
the expressions of c-FLIP and EGFR were evaluated by western
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blotting analysis after other 24 h of incubation. Fluorescein
Conjugated siRNA, consisting in a scramble sequence, was used as
a negative control.
3. Results
3.1. SAHA/TRAIL combination induced cell detachment
and apoptosis of MDA-MB231 and MCF-7 cells
Preliminary experiments were performed to evaluate the effects
exerted by SAHA and TRAIL in MDA-MB231 cells, a very aggressive
and poorly differentiated breast cancer cell line, which is negative
for ERa [26]. The effect of the compounds was also evaluated in
MCF-7 cells, a more differentiated breast cancer cell line which is
ERapositive [26]. MDA-MB231 and MCF-7 cells were treated for
various times with different concentrations of SAHA or TRAIL alone
or in combination.
Treatment of MDA-MB231 or MCF-7 cells with SAHA (0,2-2 mM)
or TRAIL (10e50 ng/ml) alone did not induce cell detachment or any
morphological change even after prolonged incubation (36e48 h)
(not shown). Instead, when MDA-MB231 cells were exposed to
combination of SAHA (2 mM) and TRAIL (50 ng/ml), about 25% of
cells were deprived of anchorage already at 8 h of treatment. The
effect then increased with the time and at 24 h detached cells
reached the percentage of 82% (Fig. 1A). Co-treatment also induced
detachment of MCF-7 cells, although the effect was observed after
a longer period of treatment (12 h) (Fig. 1B). In both the cell lines
detachment was markedly reduced by the addition of 100 mM
z-IEDT-fmk, the speciﬁc inhibitor of caspase-8, suggesting that this
caspase activity is involved in detachment of MDA-MB231 and
MCF-7 cells (Fig. 1A and B). It is interesting to note that during the
ﬁrst phase of co-treatment (0e12 h) detached cells were grouped in
small viable clusters, but when the time of treatment was prolonged
(14e24 h) the number of clustered cells diminished and signs of
apoptosis appeared.
These considerations prompted us to analyze separately
adherent from detached cells. The study of cell cycle distribution by
ﬂow cytometric analysis revealed that after 14h of treatment
with SAHA/TRAIL combination a consistent percentage of detached
MDA-MB231 cells was conﬁned in subG0/G1 phase, a condition
which is representative of cells with fragmented DNA, while
treatment with SAHA or TRAIL alone did not induce any sign
of apoptosis (Fig. 2A). Moreover, staining MDA-MB231 cells with
Hoechst 33342 revealed that co-treatment induced in a high
percentage of detached cells the presence of morphological
changes typical of apoptosis, including chromatin condensation
and nuclear fragmentation (Fig. 2 A, insets). These results were
conﬁrmed by ﬂow cytometric analysis of cells stained with annexin
V-FITC. Time course experiments showed that apoptotic effects
were limited in the ﬁrst phase of co-treatment (0e12 h), but
Fig. 1. SAHA/TRAIL combination induced detachment of MDA-MB231 (A) and MCF-7 (B). Cells were treated for different times with 2 mM SAHA or 50 ng/ml TRAIL or SAHA/TRAIL
combination without or with 100 mM IEDT-fmk. Adherent and detached cells were counted in Neubauer chamber. Detached cells were expressed as percentage of the total cells.
Results are the means  S.E. of three independent experiments. *P < 0.01 versus control.
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markedly increased between 14 and 24 h, and at 24 h apoptotic
signs appeared in about 68% of treated cells. Differently in adherent
cells only modest effects were observed also after prolonged
treatments with drug combinations. Finally, the addition of 100 mM
z-IEDT-fmk prevented both detachment of cells and the apoptotic
effects (Figs. 1 and 2B).
It is interesting to note that the percentage of detached cells
showing apoptotic signs was very low at 8 h of treatment, then
increased with the time of incubation so that at 24 h apoptotic
signs were observed in almost all the detached cells (Fig. 2C). This
result clearly suggested that apoptotic effect was secondary to cell
detachment.
Fig. 2. SAHA/TRAIL combination induced anoikis in MDA-MB231 and MCF-7 cells. Cells were treated with 2 mM SAHA or 50 ng/ml TRAIL or SAHA/TRAIL combination. Since
treatment with SAHA/TRAIL combination induced detachment of cells, in this case the effects of the drugs were analysed in both adherent (a) and detached (d) cells. (A) Flow
cytometric analysis of MDA-MB231 cells, treated with the drugs for 14 h, after staining with PI. The effects of the treatment on cell morphology observed in the insets were
ascertained after staining with Hoechst 33342. Results are representative of three independent experiments. (B) Time course of the apoptotic effect induced by SAHA/TRAIL
combination. Apoptotic cells were detected by ﬂow cytometry using the annexin V-FITC kit. *P < 0.01 versus adherent cells. (C) Percentages of MDA-MB231 or MCF-7 apoptotic cells
with respect to total detached cells at various times of co-treatment. (B and C), results are the means  S. E. of three independent experiments.
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Fig. 3. The effect of SAHA and TRAIL on TRAIL receptors and c-FLIP in MDA-MB231 and MCF-7 cells. Cells were treated with SAHA or TRAIL or SAHA/TRAIL combination. At the end,
cell extracts were prepared and analysed for Western blotting. In cells treated with SAHA/TRAIL combination the analyses were performed in both adherent (a) and detached (d)
cells. (A) The effect exerted by treatment for 14 h on the levels of DR4, DR5 and c-FLIP. Detection of actin is enclosed to demonstrate equal loading of protein for each sample.
Densitometric values are representative of three independent experiments. (B) Time course of the effect exerted by co-treatment on c-FLIPL level. Densitometric values are
expressed as percentage of control sample, which is represented by cells incubated in the absence of the drugs. (C and D) MDA-MB231 cells were transfected for 5 h with siRNA
sequence directed against c-FLIP or with siRNA scramble and then incubated for other 24 h. C). Western blotting analysis showing down-regulation of c-FLIP in c-FLIP silenced cells.
D) The effects induced in c-FLIP silenced cells by 14 h of treatment with TRAIL on cell detachment (left) and on apoptosis (right).
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In MCF-7 cells the ratio “apoptotic/detached” cells increased
with time similarly to MDA-MB231 cells (Fig. 2C), suggesting that
also in MCF-7 cells apoptosis induced by SAHA/TRAIL combination
was secondary to cell detachment. However, since the apoptotic
effects were more evident in MDA-MB231 cells, these cells were
chosen for ascertaining the mechanism of SAHA/TRAIL action.
3.2. The effects of SAHA and TRAIL on the expression
of death receptors and c-FLIP
Sensitization of cancer cells to TRAIL-induced apoptosis can
result either by the increase in the level of TRAIL receptors or by the
decrease in the level of anti-apoptotic factors such as c-FLIP or IAPs
[20,27]. Therefore, we performed western blotting experiments to
evaluate the effects of the drugs on both TRAIL receptors and c-FLIP.
Our results demonstrated (Fig. 3A) that MDA-MB231 cells exhibit
both DR4 and DR5 receptors and high levels of c-FLIPL and c-FLIPS,
the two different isoforms of c-FLIP. Also in MCF-7 cells we ascer-
tained the presence of death receptors and c-FLIP proteins, but at
lower levels (Fig. 3A). However, the expression of death receptors
was not modiﬁed by the drugs in both the cell lines. Instead
treatment with SAHA alone decreased the level of both c-FLIPL and
c-FLIPS either in MDA-MB231 or MCF-7 cells (Fig. 3A). A more
consistent effect was observed when the cells were treated with
SAHA/TRAIL combination. Down-regulation of c-FLIP was found
already at 8 h of incubation and the effect reached the maximum at
14 h (Fig. 3B).
In order to ascertain whether down-regulation of c-FLIP sensi-
tizes MDA-MB231 cells to TRAIL-induced apoptosis, cells were
transiently transfectedwith siRNA sequence directed against c-FLIP,
inducing a decrease in c-FLIP content of approximately 50%
(Fig. 3C). This down-regulation of c-FLIP sensitized the cells to
TRAIL. In fact the addition of TRAIL to silenced cells induced cell
detachment and apoptosis (Fig. 3D). These effects were not found
when the cells were transfected with siRNA scramble.
3.3. The effects of SAHA and TRAIL on the level of integrins and FAK
It is well known that cell anchorage to extracellular matrix
(ECM) is mediated mainly by integrins [28]. Upon integrin ligation,
focal adhesion-kinase (FAK) is phosphorylated and interacts with
several proteins, many of which stimulate proliferation and cellular
survival [29]. The loss of integrin engagement eliminates these
signals, thus committing detached cells to anoikis [30].
In our experiments we demonstrated that SAHA and TRAIL
neither alone nor in combination modiﬁed the levels of a5 and b1
integrin subunits (Fig. 4A), which are present at high levels in
MDA-MB231 cells and that have been reported to exert a critical
role in proliferation and migration of these cells [31e33]. Differ-
ently, SAHA/TRAIL co-treatment induced down-regulation of FAK
(Fig. 4A). This effect, which was observed already at 8 h, increased
with time reaching the maximum at 14 h (Fig. 4B). Down-
regulation of FAK was much more pronounced in detached than
in adherent cells and was not observed when the cells were treated
with the single compounds. Moreover, the addition of z-IEDT-fmk,
a speciﬁc caspase-8 inhibitor, prevented both the detachment of
cells and the decrease in FAK level induced by co-treatment
(Fig. 4A). This ﬁnding, in line with a previous observation [34],
suggests an involvement of caspase-8 in FAK cleavage. Accordingly,
inMDA-MB231 cells transfectedwith c-FLIP siRNA our results show
that treatment with TRAIL caused both activation of caspase-8 (not-
shown) and down-regulation of FAK (Fig. 4C).
c-Src is a tyrosine kinase which is involved in the phosphory-
lation and activation of FAK [35]. By means of western blotting
analysis we demonstrated that in MDA-MB231 cells SAHA and
TRAIL neither alone nor in combination modiﬁed the level of c-Src
(not shown).
3.4. The effect of SAHA and TRAIL on BimEL
Bim, a proapoptotic member of Bcl-2 family, exists in three
splice variants, short, long and extra long (BimS, BimL and BimEL,
respectively). BimEL is the major species expressed, while the other
forms are present at very low levels [36]. An important role in
modulating BimEL activity is exerted by phosphorylation of the
protein on Ser69 by ERK1/2 [37]. Phosphorylation of BimEL leads to
ubiquitination and the consequent proteasomal degradation [38].
Instead, dephosphorylated form of BimEL, which is peculiar of cells
Fig. 4. The effects of SAHA and TRAIL on the levels of a5, b1 integrins and FAK in MDA-
MB231 cells. Cells were treated with SAHA or TRAIL or SAHA/TRAIL combination. After
treatment, cells extracts were prepared and analysed for Western blotting. When the
cells were treated with SAHA/TRAIL combination, analysis was performed both in
adherent (a) and detached (d) cells. (A) The effect exerted by treatment for 14 h on the
levels of a5, b1 integrins and FAK. Detection of actin was enclosed to demonstrate
equal loading of protein for each sample. Densitometric values is representative of
three independent experiments. (B) Time course of the effect exerted by SAHA/TRAIL
combination on the level of FAK in detached cells. Densitometric values are expressed
as percentage of control sample, which is represented by cells incubated in the absence
of the drugs. Values are the means  S. E. of three independent experiments. (C) MDA-
MB231 cells were transfected for 5 h with siRNA sequence directed against c-FLIP or
with scramble siRNA. After other 24 h of incubation the cells were treated for 8 h with
TRAIL to evaluate the effect on the level of FAK.
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Fig. 5. The effects of SAHA and TRAIL on the levels of EGFR, phospho-EGFR, phospho-ERK1/2, and BimEL in MDA-MB231 and MCF-7 cells. Cells were treated with 2 mM SAHA or
50 ng/ml TRAIL or SAHA/TRAIL combination. After treatment, cell extracts were prepared and analysed for Western blotting. When the cells were treated with SAHA/TRAIL
combination, analysis was performed both in adherent (a) and detached (d) cells. (A) The effects of treatment for 14 h on the levels of EGFR, phospho-EGFR, phospho-ERK1/2 and
BimEL. (B) Time course of the effects exerted by SAHA/TRAIL combination on the levels of phospho-EGFR and phospho-ERK1/2. Densitometric values, expressed as percentage of
control, are the means  S. E. of three independent experiments. (C) MDA-MB231 cells were transiently transfected for 5 h with siRNA sequence directed against EGFR and
employed in comparison with cells transfected with siRNA scramble to evaluate after other 24 h of incubation the effect of EGFR silencing on the level of EGFR, phospho-EGFR,
phopho-ERK1/2 and BimEL (D) The effect of treatment of MDA-MB231 cells for 8 h with various concentrations of AG1478 on the levels of phospho-EGFR, phospho-ERK1/2
and BimEL. (A, C and D). Detection of actin was enclosed to demonstrate equal loading of protein for each sample. Densitometric values are representative of three independent
experiments.
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addressed to anoikis [40], is capable of stimulating BAX oligomer-
ization thus antagonizing Bcl-2 function [40].
Two bands of BimEL with different electrophoretic mobility
were detected by western blotting analysis (Fig. 5A) in untreated
MDA-MB231 and MCF-7 cells: a slow-migrating band at high
intensity, which corresponds to phosphorylated form [41], and
a fast-migrating one at low intensity, which is related to dephos-
phorylated protein [41]. In agreement with the observation of Bali
et al.[42], our results demonstrated that treatment with SAHA
alone caused a modest increase in the level of both the forms of
BimEL either in MDA-MB231 or in MCF-7 cells. However, when the
cells of both the lines were treated with SAHA/TRAIL combination
(14 h) amarked decrease in the intensity of the band corresponding
to phospho-BimEL together with a concomitant increase in the
dephosphorylated form was observed. These changes were more
pronounced in detached than in adherent cells (Fig. 5A).
3.5. Down-regulation of EGFR plays a role in anoikis induced
by SAHA/TRAIL combination
Among the molecules which can mediate survival signals at the
membrane level, epidermal growth factor receptor (EGFR) exerts an
important role in stimulating the proliferation of MDA-MB231 cells
[43]. It has been shown that dimerization and autophosphorylation
of EGFR represent the initial and essential events in the activation
of the receptor in response to EGF binding [44]. EGFR activation
results in phosphorylation of ERK1/2 [44], which in turn phos-
phorylates BimEL [45].
As shown in Fig. 5A, high levels of both EGFR and phospho-
ERK1/2 were detected in untreated MDA-MB231 cells, while in
MCF-7, in agreement with the observation of Frogne et al.[46], low
levels of these proteins were found. The treatment reduced the
levels of EGFR, phospho-EGFR and phospho-ERK1/2. The decre-
ments were already observed when the cells were treated with
SAHA alone and became more consistent after SAHA/TRAIL treat-
ment (Fig. 5A). The effects appeared in both the cell lines at 8 h of
treatment and increased up to 14 h (Fig. 5B for MDA-MB231 cells).
These results led us to hypothesize that the increase in the
dephosphorylated form of BimEL induced by SAHA/TRAIL combi-
nation can be a consequence of the inhibition of EGFR signalling. To
conﬁrm this hypothesis, MDA-MB231 cells were transfected with
siRNA sequence directed against EGFR. In response to this treatment
EGFR level diminished to about 40% of the control (Fig. 5C). In close
correlation also the level of both phospho-EGFR and phospho-ERK1/
2 decreased with respect to the control together with the level of
phospho-BimEL, while dephosphorylated form of BimEL concomi-
tantly increased (Fig. 5C). Similar results were obtained when MDA-
MD231 cells were treated for 8 h with different concentrations of
AG1478 (Fig. 5D), a speciﬁc tyrosine kinase inhibitor of EGFR [47].
Therefore, these results strongly suggest that down-regulation of
EGFR, induced by SAHA-TRAIL combination, can be responsible for
activation of BimEL and consequently for induction of anoikis.
3.6. The role of mitochondria in anoikis induced
by SAHA/TRAIL combination
It has been reported that dephosphorylated form of BimEL binds
Bax favouring its oligomerization [39]. In turn, Bax may interact
with mitochondrial proteins like VDAC and/or ANT to regulate the
permeability transition pore (PTP) [48]. To evaluate whether
treatment with SAHA/TRAIL combination induced dissipation of
mitochondrial membrane potential, we utilized the ﬂuorescent
lipophilic dye DiOC6. As shown in Fig. 6A, co-treatment resulted in
an increase in the percentage of depolarised cells. The effect was
observed only in detached cells andwas not induced in cells treated
with the single compounds.
Finally, we ascertained by western blotting analysis that
treatment of MDA-MB231 cells with SAHA/TRAIL combination
induced activation of both caspases8 and3. As shown in Fig. 6B,
co-treatment decreased the level of procaspase-8 with the
concomitant appearance of the cleaved form of caspase-8. More-
over, co-treatment also induced cleavage of procaspase-3. However,
cleavage of procaspase-8 was already observed at 8 h of treatment,
while that of caspase-3 appeared only after a more prolonged
period of incubation (14 h) (Fig. 6C). Activation of caspases-8 and -3
was also observed in MCF-7 treated with SAHA/TRAIL combination
(not shown).
3.7. The effects of SAHA and TRAIL on MDA-MB231 cells
cultured in poly-HEMA
Several studies report that MDA-MB231 cells are resistant to
anoikis [39,41], because are capable of growing in an anchorage-
independent manner. To conﬁrm these data we carried out exper-
iments in which adhesion of MDA-MB231 cells was prevented by
culturing them in poly-HEMA, an inert polymer impeding cell
attachment [49]. Our results show that MDA-MB231 cells, cultured
in poly-HEMA, grew in cluster and did not present morphological
alterations (control cells in Fig. 7A), conﬁrming that MDA-MB231
cells survive when are deprived of anchorage. However, when the
cells cultured in poly-HEMA were treated with SAHA/TRAIL
combination, but not with SAHA or TRAIL alone, clear apoptotic
signs were observed. In fact, cytoﬂuorimetric analysis showed
signiﬁcant percentages of cells in subG0/G1 phase at 14 h of
treatment. This effect was accompanied bymorphological evidence
of apoptosis (Fig. 7A).
Western blotting analysis showed that MDA-MB231 cells
cultured in poly-HEMA contain high levels of EGFR, phospho-EGFR,
phospho-ERK1/2, FAK and c-FLIP. The levels of these factors mark-
edly lowered after treatment with SAHA/TRAIL combination, while
the level of the dephosphorylated form of BimEL increased (Fig. 7B).
Finally, in order to clarify whether activation of EGFR signalling
plays a role in anoikis resistance of MDA-MB231 cells, we cultured
in poly-HEMA MDA-MB231 cells, which had been previously
transfected with siRNA sequence directed against EGFR. Cyto-
ﬂuorimetric analysis demonstrated that down-regulation of EGFR
sensitizedMDA-MB231 cells toTRAIL induced apoptosis (Fig. 7C). In
fact, when transfected cells were treated for 14 h with TRAIL alone
a consistent percentage of cells (33%) resulted conﬁned in subG0/
G1 phase, whereas this event was not observed in cells transfected
with siRNA scramble.
4. Discussion
Several breast cancer cell lines, such as ERa-negative MDA-
MB231 cells and ERapositive MCF-7 cells, exhibit resistance to
Fig. 6. The effects of SAHA and TRAIL on mitochondrial membrane potential and caspase activities in MDA-MB231 cells. Cells were treated with 2 mM SAHA or 50 ng/ml TRAIL or
SAHA/TRAIL combination. After co-treatment, analysis was performed both in adherent (a) and detached (d) cells. (A) Co-treatment for 14 h induced dissipation of mitochondrial
membrane potential (DJm), evaluated by ﬂow cytometry using lipophilic dye DioC6. Results are representative of three independent experiments. (B) Co-treatment for 14 h
induced activation of caspases-8 and -3. The levels of the proteins were analysed byWestern blotting using speciﬁc antibodies. Detection of actin was enclosed to demonstrate equal
loading of protein for each sample. Densitometric values are representative of three independent experiments (C) Time course of the effects exerted by co-treatment on the levels of
pro-caspases-8 and 3, analysed by western blotting. Densitometric values, expressed as percentage of control, are the means  S. E. of three independent experiments.
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Fig. 7. The effects of SAHA and TRAIL on MDA-MD231 cells cultured on poly-HEMA. Cells were seeded on 6-well poly-HEMA-coated tissue culture dishes to produce non-anchored
cells. After 24 h of growth, cells were treated with SAHA or TRAIL alone or in combination for another 14 h. (A) Flow cytometric analysis of MDA-MB231 cells, treated with the drugs
for 14 h after staining with PI. The effects induced by treatment on cell morphology, as shown by optical microscope, were reported in the insets. Results are representative of three
independent experiments. (B). The effects of co-treatment on the levels of FAK, EGFR, phospho-EGFR, phopho-ERK1/2, BimEL and c-FLIP, ascertained by western blotting analysis
using speciﬁc antibodies. Detection of actin was enclosed to demonstrate equal loading of protein for each sample. Densitometric values are representative of three independent
experiments. (C) MDA-MB231 cells were transfected for 5 h with siRNA sequence directed against EGFR or with siRNA scramble and then cultured on poly-HEMA. After other 24 h of
incubation the cells were treated with TRAIL for 14 h to evaluate the effect on apoptosis.
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apoptosis induced by TRAIL signalling [22,50]. This paper shows
that SAHA, an effective inhibitor of histone deacetylases, sensitized
both MDA-MB231 and MCF-7 cells to TRAIL-induced apoptosis,
since treatment with SAHA/TRAIL combination induced detach-
ment of cells and apoptosis of detached cells in both the cell lines.
Time course experiments demonstrated that already at 8 h of
treatment with SAHA/TRAIL combination about 25% of MDA-MB231
cells were deprived of anchorage and grouped in viable clusters,
while signs of apoptosis (chromatin condensation and fragmenta-
tion) appeared at 12e14 h of treatment and were observed only in
detached cells. This eventwas peculiar of anoikis, a formof apoptosis
that occurs in various normal cell types after detachment from their
proper substratum [24]. Similar observations were also made for
MCF-7 cells treated with SAHA/TRAIL combination.
In order to clarify how the treatment sensitizes the cells of both
the lines to TRAIL-signalling pathway we ascertained that neither
SAHA nor TRAIL, either alone or in combination, modiﬁed the level
of both DR4 and DR5. However, treatment with SAHA alone
decreased the level of the anti-apoptotic factor c-FLIP. Because
c-FLIP prevents the activation of procaspase-8 at the DISC [51], its
down-regulation was responsible for activation of caspase-8. Such
an effect became more consistent when the cells were treated with
SAHA/TRAIL combination.
Our results also demonstrated that SAHA and TRAIL either
alone or in combination were unable to exert any effect on the
levels of a5 and b1 integrin subunits, which have been reported to
be up-regulated in MDA-MB231 cells and seem to be involved in
the survival and migration of these cells [31,32]. However, we
cannot exclude that SAHA/TRAIL co-treatment modiﬁed the levels
of other integrin subunits, since aberrant expression of several
other integrins has been shown in breast cancer cell lines [52,53].
However, our results demonstrated that SAHA/TRAIL combination
markedly reduced the level of FAK, the tyrosine kinase which is
present at sites of integrin/ECM attachment and plays a key role
in mediating integrin signalling [54]. The decrease in FAK level
was already observed at 8 h of treatment and was prevented by
IEDT-fmk, the speciﬁc inhibitor of caspase-8. This observation was
in line with the ﬁnding that FAK is a target of caspases [34]. It has
been reported that the inhibition of FAK expression with anti-
sense oligonucleotides or dominant-negative leads to cell
rounding, detachment and anoikis [54,55]. Thus, the cleavage of
FAK by activation of caspase-8 could induce the disassembly of
focal adhesion complex favouring cell detachment. Therefore,
down-regulation of c-FLIP, which induced activation of caspase-8
and down-regulation of FAK, could be considered as an initial
event to provoke detachment of the cells. In line with this
consideration, silencing of c-FLIP in MDA-MB231 cells favoured
detachment of cells induced by treatment with TRAIL alone.
In breast cancer cells EGF receptor is capable of favouring
proliferation, migration and cell survival as well as inhibiting
apoptosis [43]. It is known that MDA-MB231 cells contain a high
level of EGFR [43]. This can be a consequence of the absence in
these cells of estrogen receptor a, because it has been demonstrated
an inverse relationship between the presence of estrogen receptor
a and the level of EGFR [43]. This paper demonstrates that SAHA
decreased the level of both EGFR and its phosphorylated form. This
result is in line with the observation of Zhou et al. [56], showing
that in breast cancer cells SAHA down-regulated EGFR by destabi-
lizing its mRNA. Our results also showed that the decrease induced
by SAHA was potentiated by addition of TRAIL, although the
mechanism by which co-treatment can induce this effect is
unknown at the moment.
It has been shown that down-regulation of EGFR reduces
ERK1/2 phosphorylation with the consequent increase in the
dephosphorylated and active form of BimEL, an effect which plays
an important role in the induction of anoikis [57]. Our results
demonstrated that the same effects were determined in MDA-
MB231 cells by the treatment with SAHA/TRAIL combination.
Thus down-regulation of EGFR could be responsible for accumu-
lation of the dephosphorylated form of BimEL. This conclusion was
supported by the ﬁnding that EGFR down-regulation induced in
MDA-MB231 cells by speciﬁc siRNA markedly reduced phosphor-
ylated forms of EGFR, ERK1/2 and BimEL, while increased
dephosphorylated form of BimEL. Similar results were observed
using AG1478, a speciﬁc inhibitor of the tyrosine kinase activity of
EGFR. In addition, because it is known that phosphorylation of
ERK1/2 can be also dependent on FAK activation [58], it is possible
that FAK cleavage, induced by co-treatment, could play a role in
ERK1/2 inhibition and BimEL activation. Finally, in agreement with
the observations of Frogne et al. [46], we demonstrated that MCF7
cells express low levels of EGFR, phospho-EGFR and phospho-
ERK1/2. SAHA/TRAIL co-treatment markedly reduced the levels of
these factors and concomitantly increased the dephosphorylated
form of BimEL, thus suggesting that also in MCF-7 cells down-
regulation of EGFR can be correlated with accumulation of the
active form of BimEL.
It is known that BimEL in the dephosphorylated form exerts
apoptotic function either by inhibiting the anti-apoptotic factor Bcl-2
or favouring BAX oligomerization [36]. Bcl-2 inhibition and BAX
activation are responsible for the loss of mitochondrial membrane
potential [59]. Thus, the increase in the dephosphorylated form of
BimEL, induced by SAHA/TRAIL combination, might assume a partic-
ular relevance in the loss of Djm and the consequent activation of
caspase-3, observed in detached MDA-MB231 cells treated with the
drugs in combination.
Many normal cell types, including epithelial cells, undergo
anoikis upon detachment from their proper substratum [24]. In
contrast, many malignant cells survive after cell detachment [60].
Anoikis-resistance contributes to metastasis allowing cancer cells
to survive in the blood stream and invade distant sites [60]. It has
been reported that MDA-MB231 cells are resistant to anoikis
[41,61], an event which can be correlated with the activation of
survival pathways [39,61]. Our results agree with this conclusion,
since MDA-MB231 cells survive and proliferate when cultured in
poly-HEMA. These cells contain high levels of both EGFR and FAK
and low basal levels of the dephosphorylated form of BimEL.
Moreover, down-regulation of EGFR sensitizes MDA-MB231 cells,
cultured in poly-HEMA, to TRAIL-induced apoptosis. Therefore, our
results suggest that high levels of EGFR can prevent MDA-MB231
cells from anoikis but do not exclude that also high levels of FAK
can be responsible for anoikis resistance of MDA-MB231 cells. This
conclusion is in line with recent observations showing that dual
inhibition of FAK and EGFR cooperatively enhanced apoptosis in
human breast cancer cell lines via inhibition of signalling that
involve both AKT and ERK1/2 pathways [34]. Finally, our results
show that treatment with SAHA/TRAIL combination induced
apoptosis of MDA-MB231 cells cultured in poly-HEMA, suggesting
that this drug combination was capable of restoring anoikis sensi-
tivity of these cells. This effect was correlated with a marked
decrease in the levels of FAK, EGFR and phospho-ERK1/2, as well as
with an increase in the dephosphorylated form of BimEL.
It is known that ERanegative forms of breast cancer are more
aggressive than ERapositive ones. Moreover, ERanegative forms
are unresponsive to endocrine therapy and resistant to anoikis. Our
results demonstrate that SAHA/TRAIL combination is effective in
inducing anoikis in both ERapositive MCF-7 and ERanegative
MDA-MB231 breast cancer cells. The observation that treatment
with SAHA and TRAIL restores sensitivity to anoikis in MDA-MB231
cells suggests a new and attractive pharmacological tool for the
treatment of breast cancer.
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Recently, it has been shown that SAHA/TRAIL combination
inhibited the growth of xenograft tumors derived from MDA-
MB468 cells, another ERanegative breast cancer cell line [62].
We have in program a new study in order to ascertain in nude mice
bearing tumors derived from MDA-MB231 cells the anticancer
potential of SAHA/TRAIL combination, the molecular mechanism of
this effect and the possible advantageous association with other
antitumor factors.
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